Multiple myeloma - lenalidomide (TA171)
Fast, easy summary view of NICE guidance on 'blood and bone marrow cancers'
Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenalidomide (used together with a medicine called dexamethasone) is recommended as a possible treatment for people with multiple myeloma who have already had at least two other treatments. The manufacturer of lenalidomide has agreed to cover the cost of the drug for people who stay on treatment for more than 26 cycles (normally a period of 2 years).
Healthcare professionals should not stop prescribing lenalidomide for people with multiple myeloma who were already taking it when the guidance was issued, but who have not already had two or more other treatments. These people should be able to carry on taking lenalidomide until they and their healthcare professional(s) decide that it is the right time to stop treatment.
Following the BBC documentary The Price of Life broadcast on 17 June, NICE has published guidance on the use of lenalidomide for multiple myeloma on its website ahead of the scheduled publication date. The guidance will be formally issued to the NHS when we launch other guidance on 24 June 2009. Accordingly, the Secretary of State's direction requiring NHS organisations to make funding available for NICE recommended treatments within 3 months of final guidance being published will begin ON 24 June.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: blood and bone marrow cancers
- Multiple myeloma - lenalidomide: review decision - November 2012
- Multiple myeloma - lenalidomide: review proposal - March 2012
- TA171 Multiple myeloma - lenalidomide: review update - November 2011
- TA171 Multiple myeloma - lenalidomide: review update - January 2011
- NICE guidance recommends lenalidomide for multiple myeloma
This page was last updated: 15 April 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA171 Lenalidomide ar gyfer myeloma ymledol mewn pobl sydd wedi cael triniaeth flaenorol: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.